ArticleAmerican journal of surgery2015
A cost analysis of a pancreatic cancer screening protocol in high-risk populations.
Article in American journal of surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Economic evaluations of early detection strategies for pancreatic cancer: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Pooled it
- Cost-Effectiveness and Clinical Utility of Pancreatic Cancer Non-Invasive Test in New-Onset Diabetes.ClinicoEconomics and outcomes research : CEOR · 2026Article
- An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment.The British journal of radiology · 2025Review
- Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.JCO oncology practice · 2024Article
- Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records.eLife · 2023Article
- Pancreatic Cancer and Detection Methods.Biomedicines · 2023Review
- A Comparison of Single Dimension and Volume Measurements in the Risk Stratification of Pancreatic Cystic Lesions.Journal of clinical medicine · 2023Review
- Pancreatic cancer screening in high-risk individuals with genetic susceptibility.Hepatobiliary surgery and nutrition · 2023Article
- Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort.United European gastroenterology journal · 2023Article
- Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.Gastroenterology · 2022Review
- Designing optimal allocations for cancer screening using queuing network models.PLoS computational biology · 2022Article
- Efficacy of Dialectical Comprehensive Treatment of Traditional Chinese Medicine in Patients with Chronic Stable Heart Failure: A Randomized Controlled Trial.Cardiology research and practice · 2022Article
- Review
- Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review.Pancreas · 2021Review
- Pancreatic Cancer and Diabetes Mellitus.Current treatment options in gastroenterology · 2018Review
- Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes.Gastroenterology · 2018 · on this mapArticle
- Design and Success of a 21st Century Cancer Education Program at the University of Louisville.Journal of cancer education : the official journal of the American Association for Cancer Education · 2018Article
- Precious Data: Interim Report from the Jefferson Pancreas Tumor Registry.Journal of pancreatic cancer · 2018Article
- Nationwide survey of hereditary pancreatitis in Japan.Journal of gastroenterology · 2018Article
- A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes.Gastroenterology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundPancreatic cancer is the 4th leading cause of cancer death in the United States. A screening protocol is needed to catch early-stage, resectable disease. This study suggests a protocol for high-risk individuals and assesses the cost in the context of the Affordable Care Act.
methodsMedicare and national average pricing were used for cost analysis of a protocol using magnetic resonance imaging/MRCP biannually in high-risk groups.
resultsCosts per year of life added" based on Medicare and national average costs, respectively, are as follows: $638.62 and $2,542.37 for Peutz-Jeghers syndrome, $945.33 and $3,763.44 for hereditary pancreatitis, $1,141.77 and $4,545.45 for familial pancreatic cancer and "p16-Leiden" mutations, and $356.42 and $1,418.92 for new-onset diabetes over age 50 with weight loss or smoking.
conclusionsA screening program using magnetic resonance imaging/MRCP is affordable in high-risk populations. The United States Preventive Services Task Force must re-evaluate its pancreatic cancer screening guidelines to make screening more cost-effective for the individual.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.